The Food and Drug Administration (FDA) announced Friday that none of the influenza vaccine manufactured by the Chiron Corporation for the
The purpose of the FDA inspection was both to evaluate Chiron's investigation, testing and assessment of the defects detected in nine of the one hundred lots of their finished flu vaccine (Fluvirin) manufactured for this year's flu season and also to evaluate their determination that the risk of defects was confined to those specific lots.
The safety of the vaccine supply is of the highest priority to FDA and the Department of Health and Human Services. FDA has provided Chiron with its inspectional observations and has met with the company to evaluate their response and assure that the necessary corrective actions are taken. The FDA will work with Chiron and the
The Department of Health and Human Services will continue to exhaust every avenue to secure more flu vaccine for this season. Literally every known manufacturer of flu vaccine in the world is being contacted and some progress is being made. Additionally, the quarantined lots of Chiron vaccine already in the United States are being ever further evaluated. We do not want to create false hope but we want to explore every option, FDA officials said.